Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock
This article was originally published in The Gray Sheet
Executive Summary
Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49
You may also be interested in...
AngioJet Falls Short On Prophylactic Use; Possis Fortifies Current Indication
Possis Medical will present an analysis of baseline patient characteristics that may have contributed to adverse AiMI study results at TCT 2004 in Washington, D.C. Sept. 27-Oct. 1
AngioJet Falls Short On Prophylactic Use; Possis Fortifies Current Indication
Possis Medical will present an analysis of baseline patient characteristics that may have contributed to adverse AiMI study results at TCT 2004 in Washington, D.C. Sept. 27-Oct. 1
Ocular Envisions Greater Share Of U.S. Spherical Contact Lens Market
Ocular Sciences aims to challenge Johnson & Johnson for dominion of the spherical soft contact lens market with its Biomedics55 Premier lens, which currently is being rolled out to customers